Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Current Deferred Revenue: 2020-2022

Historic Current Deferred Revenue for GeneDx Holdings (WGS) over the last 2 years, with Dec 2022 value amounting to $40,000.

  • GeneDx Holdings' Current Deferred Revenue fell 91.54% to $40,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $40,000, marking a year-over-year decrease of 91.54%. This contributed to the annual value of $40,000 for FY2022, which is 91.54% down from last year.
  • According to the latest figures from Q4 2022, GeneDx Holdings' Current Deferred Revenue is $40,000, which was down 98.58% from $2.8 million recorded in Q3 2022.
  • In the past 5 years, GeneDx Holdings' Current Deferred Revenue registered a high of $3.8 million during Q1 2022, and its lowest value of $40,000 during Q4 2022.
  • Its 3-year average for Current Deferred Revenue is $2.1 million, with a median of $2.8 million in 2021.
  • Examining YoY changes over the last 5 years, GeneDx Holdings' Current Deferred Revenue showed a top increase of 472.82% in 2022 and a maximum decrease of 91.54% in 2022.
  • Quarterly analysis of 3 years shows GeneDx Holdings' Current Deferred Revenue stood at $3.8 million in 2020, then crashed by 87.59% to $473,000 in 2021, then slumped by 91.54% to $40,000 in 2022.
  • Its Current Deferred Revenue stands at $40,000 for Q4 2022, versus $2.8 million for Q3 2022 and $3.2 million for Q2 2022.